The only other CBD drug for 3 rare forms of epilepsy is on track to do $1bn of sales next year. Our trials aim to widen prescribing to other forms of epilepsy. Worth thinking about.
The calibre of the Team is 2nd to none and we really are moving along with the sectorial mover shakers so it top of the tree global moves in place for sure